- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01543074
Dietary Histone Deacetylase Inhibitors (HDAC)
Dietary Histone Deacetylase (HDAC) Inhibitors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study participants attend a pre-study meeting either individually or with several other potential volunteers according to their preference. The study is described in detail and participants are given the opportunity to ask questions. If participants agree to participate, they will sign the consent form. Height and weight will be measured privately.
Food diary forms will be distributed and taught how to use. A 4ml (1 tsp) blood sample will be drawn for a pre-study blood chemistry, CBC and thyroid tests. Samples for all clinical labs done during the study will be sent to Good Samaritan Hospital, a CLIA-certified laboratory, on a fee-for-service basis.
The study MD will evaluate the lab results. If the tests are abnormal as determined by the study MD, the participant will be excluded from the study and advised to see their doctor for evaluation.
Subjects will observe dietary restrictions starting one week before Day 1 of the study and continuing through Day 14 (total of 3 weeks). Dietary restrictions are listed on the last page of the diet recall forms.
Women with negative urine pregnancy test on the morning of Day 1 will be enrolled in the study. About 20 ml fasting blood will be drawn on the morning of Day 1. Breakfast will be provided and 3 capsules given to swallow. (One capsule will be garlic oil or garlic oil placebo, the other two will be BSE or BSE placebo.) No eating or drinking (except water) until the next blood draws at 1,3 6 hours after breakfast.
Participants will come to the study site for the next seven days to consume the standard breakfast and study capsules, or we may send the breakfast and study capsules home with participants for the weekend. Blood will be sampled immediately before breakfast on day 7 and again at 1, 3, 6, 24 and 48 hours later. We will provide a standardized lunch to all participants on Days 1 and 7. Additional blood draws will occur at the end of week 2 (i.e. on day 14 of the study). The study will end after 2 weeks.
Participants will fill out a dietary recall form three random times during the study on two week days and one weekend day.
Urine will be collected on the following schedule: Day 1, 0-3 hours, 3-6 hours, 6-12 hours,12-24 hours, 24-48 hours; Day 7, 0-3 hours, 3-6 hours, 6-12 hours, 12-24 hours, 24-48 hours. Total urine from each interval will be collected and pooled in separate containers. We will provide the proper containers for urine collection. Urine may be stored at room temperature.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oregon
-
Corvallis, Oregon, United States, 97331
- Oregon State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- age: 20 and older
- body mass index 19-30 kg/sq m
- willingness to maintain normal exercise and activity patterns
- willingness to avoid cruciferous vegetables and garlic and related foods (onion etc.) 1 week before and 2 weeks during the trial for a total of 3 weeks
Exclusion criteria:
- tobacco use within the past three months
- engaging in aerobic activity more than 6 hours per week
- being vegetarian or having other restrictive dietary requirements
- consuming >3 alcoholic beverages/day or >10 per week
- having history of diabetes or uremia or other known metabolic disease
- participating in another dietary study within the past three months
- for women, being pregnant or breastfeeding
- gastrointestinal diseases that could increase gut permeability, including Crohn's disease, ulcerative colitis, gastritis
- taking dietary supplements other than those given in the study
- abnormal liver function, CBC, or thyroid values
- individuals taking any drug or medication, prescription or over the counter, including Isoniazid, Saquinavir, Warfarin, Cyclosporine, Acetaminophen, Oxazepam, medications used for HIV/ AIDS, blood clotting, birth control pills, fish oil and medications metabolized by CYPs (CYP1A2, CYP2E1 and CYP3A4) during the dosing period of 1 week and 48 h prior to and after dosing. Exceptions may be made by the study MD and the PI if in their opinion a medication will not interfere with the scientific validity of the study. The study MD will evaluate a medication on a case-by-case basis to determine that efficacy and safety are not adversely affected.
- Individuals who are known to have problems with blood clotting or increased bleeding, including hemophiliacs or anyone recently undergoing or recovering from a surgical procedure.
- soy or garlic allergy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: BSE placebo & garlic oil placebo
Two BSE placebo capsules and one garlic oil placebo capsule per day for seven days
|
2 pills = 0 micromoles of Sulforaphane/day
Other Names:
1 pill = 0 mg garlic oil/day
Other Names:
|
|
Active Comparator: garlic oil plus BSE placebo
one garlic oil capsule plus 2 BSE placebo capsules per day for seven days
|
2 pills = 0 micromoles of Sulforaphane/day
Other Names:
1 pill = 30 mg garlic oil/day
Other Names:
|
|
Active Comparator: BSE plus garlic oil placebo
two BSE capsules plus one garlic oil placebo capsule per day for seven days
|
1 pill = 0 mg garlic oil/day
Other Names:
2 pills = 200 micromoles of Sulforaphane/day
Other Names:
|
|
Active Comparator: BSE & Garlic Oil
two BSE and one garlic oil capsule per day for seven days
|
1 pill = 30 mg garlic oil/day
Other Names:
2 pills = 200 micromoles of Sulforaphane/day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cmax of Sulforaphane and Its Metabolites in Blood
Time Frame: Before breakfast (0 hours) and 1, 3 and 6 hours after breakfast & pills on Days 1 & 7, and before breakfast on Days 8, 9 and 14.
|
The levels of "Sulforaphane and its metabolites (combined)" in blood was measured using Liquid Chromatrography-Mass Spectrometry (LC-MS) methods.
Cmax (mean +/- SD) values are shown in the "Outcome Measure Data Table".
|
Before breakfast (0 hours) and 1, 3 and 6 hours after breakfast & pills on Days 1 & 7, and before breakfast on Days 8, 9 and 14.
|
|
Tmax of Sulforaphane and Its Metabolites in Blood
Time Frame: Before breakfast (0 hours) and 1, 3 and 6 hours after breakfast & pills on Days 1 & 7, and before breakfast on Days 8, 9 and 14.
|
The levels of "Sulforaphane and its metabolites (combined)" in blood was measured using Liquid Chromatrography-Mass Spectrometry (LC-MS) methods.
The time to achieve highest plasma concentration (Tmax) is shown in the "Outcome Measure Data Table".
|
Before breakfast (0 hours) and 1, 3 and 6 hours after breakfast & pills on Days 1 & 7, and before breakfast on Days 8, 9 and 14.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Histone Acetylation
Time Frame: 6 h
|
Histone acetylation was measured by immunoblotting the levels of acetylated histone H4K12 in the circulating peripheral blood mononuclear cells (PBMCs) of subjects who consumed either placebo, garlic oil, BSE, or BSE+garlic oil.
The fold increase in acetylated histone H4K12 in the different groups is shown in the "Outcome Measure Data Table".
|
6 h
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Roderick Dashwood, PhD, Texas A&M University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA122959
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Histone Deacetylase (HDAC) Activity
-
University of British ColumbiaRecruitingImmune Functions | Histone Deacetylase (HDAC) Activity | Ketosis, MetabolicCanada
-
Asan Medical CenterCompletedGastric Cancer | Histone Deacetylase InhibitorKorea, Republic of
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Not yet recruitingChemotherapy | Bladder Cancer | Histone Deacetylase Inhibitor | EntinostatChina
-
Li ZhimingNot yet recruitingDouble Express Diffuse Large B-cell Lymphoma | Histone Deacetylase Inhibitor | BTK InhibitorsChina
Clinical Trials on BSE placebo
-
Pusan National University Yangsan HospitalRecruitingCognitive Dysfunction | Cognitive DeclineSouth Korea
-
McGill University Health Centre/Research Institute...McGill University; Heart and Stroke Foundation of CanadaActive, not recruitingPregnancy Complications | Pre-Eclampsia | Hypertension, Pregnancy-Induced | Breastfeeding | Hypertensive Disorder of PregnancyCanada
-
Julie E. Bauman, MD, MPHNational Cancer Institute (NCI)CompletedHealthy SubjectUnited States
-
Agri Ibrahim Cecen UniversityCompletedTesticular NeoplasmsTurkey
-
Eastern Mediterranean UniversityActive, not recruitingCancer | Breast Cancer | Nursing Caries | Awakening Early | Breast Self-ExaminationCyprus
-
Saglik Bilimleri UniversitesiCompleted
-
Marmara UniversityNot yet recruitingBreast Cancer Awareness and BSE in Visually Impaired WomenTurkey
-
University of California, Los AngelesCompletedAllergic Airway DiseaseUnited States
-
John KirkwoodCompletedMelanoma | Atypical NeviUnited States